Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
Open Access
- 2 December 2021
- Vol. 6 (6) , 100315
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma
- National Cancer Institute
- Hamad Medical Corporation
This publication has 46 references indexed in Scilit:
- Optic Neuropathy and Blindness Associated With Crizotinib for Non–Small-Cell Lung Cancer With EML4-ALK TranslocationJournal of Clinical Oncology, 2015
- The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010Drug Safety, 2014
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinomaBMC Cancer, 2013
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 2009
- A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactionsPharmacoepidemiology and Drug Safety, 2002
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001
- Chemotherapy for non-small cell lung cancerBMJ, 1995
- Patient noncompliance with self-administered chemotherapyCancer, 1990